Our pipeline includes one drug candidate and several compounds in different stages of pre-clinical study.
Our proprietary SIGMACEPTOR™ Discovery Platform produced small molecule drug candidates with unique modes of action, based on our understanding of sigma receptors. Sigma receptors may be targets for therapeutics to combat many human diseases, including Alzheimer’s disease. When bound by the appropriate ligands, sigma receptors influence the functioning of multiple biochemical signals that are involved in the pathogenesis (origin or development) of disease.
Rich Pipeline in Alzheimer’s and Oncology
[trx_image url=”http://anavex.com/wp-content/uploads/2018/02/Anavex-September-2017-Pipeline-slide.png” shape=”square”]